COPD

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.

Dr. Rizzo provides a look into the current methods of COPD screening, and how patient treatment potential is changed.

How do at-risk exacerbation patients present, and what developing therapies could benefit them?

Investigative triple therapy PT010 from AstraZeneca has reached primary outcome results versus a pair of standard dual inhaled therapies.

What is the large-scale study looking to bring to clinical respiratory health understanding?

In what ways do the respiratory conditions differentiate in progression and care options?

A 600-city analysis of particulate matter found daily exposure is linked to worsened mortality rates, particularly in areas with higher mean temperatures.

A new study found significantly greater COPD development risk among middle-aged women who eat processed meat—and doubly worse risk for those who also smoke and have unhealthy diets.

Analysis from the CARDIA Lung study found patients with worsened FEV1 are at greater risk for emphysema, regardless of their smoker status.

Study of more than 650 COPD patients found that CRP-guided prescribing resulted in a lower percentage of patients who reported antibiotic use.

A recent study of more than 300,000 found that exposure to outdoor air pollution is linked to decreased lung function and an increased risk of COPD.

Regardless of which care provider is diagnosing and treating the patient, all must be aware of the treatment access burdens.

After showing the ability to regain patients' senses of smell and taste in a pair of phase 3 trials, the biologic becomes the first indicated for CRSwNP.

A new pooled cohort analysis supports the longheld threshold of < .70 FEV1:FVC ratio to indicate patient risks from COPD-related events.

A three-arm clinical trial of the SAMBA program showed that screening for and tailoring to individuals' asthma needs improves their condition management.

New findings better evidence the link between long-term COPD exacerbations and poor patient sleep quality. How well-understood is the association between sleep and pulmonary conditions?

Overall rates of pulmonary rehabilitation rose in areas with greater program density, but rates for African Americans remained low despite greater program density.

Mental health disorders are highly prevalent in certain patients with COPD&mdash;and their effect can limit lung function therapy benefit.

Does it matter whether federal and state regulations allow for a significant user population?

High-risk LIVE scores for patients with COPD were associated with higher all-cause mortality and higher rates of referral to palliative care.